摘要
本研究旨在比较eIF4E在正常人和白血病患者中的表达水平,了解eIF4E是否在白血病的发生和发展中起到一定的作用。收集10例正常人和76例白血病患者的外周血细胞标本,76例患者包括39例急性髓系白血病,15例慢性髓系白血病和22例急性淋巴细胞白血病,分离标本中的白细胞,分别通过实时定量PCR和Western blot检测eIF4E在mRNA和蛋白质水平的表达变化。结果表明,就eIF4E mRNA绝对表达水平而言,在急性髓系白血病、急性淋巴细胞白血病及慢性髓系白血病急变期,其表达增高,与正常对照比较有显著性差异(P<0.05);在慢性髓系白血病慢性期,其表达水平无明显改变,在慢性髓系白血病加速期,其表达水平虽有所上调,但与正常对照无显著性差异。就eIF4E mRNA相对表达水平而言,在慢性髓系白血病、急性淋巴细胞白血病及除M4、M5之外的急性髓系白血病中,其表达均无显著性变化。eIF4E蛋白质表达在急性髓系白血病、急性淋巴细胞白血病、慢性髓系白血病加速期和急变期中均有不同程度的增高,与正常对照比较有显著性差异(P<0.05)。结论:虽然eIF4EmRNA相对表达水平在大多数白血病中并无显著性改变,但是eIF4E mRNA绝对表达水平及其蛋白质水平在大多数白血病中均显著性上调。因此推测,eIF4E可能对白血病的发生和发展起到一定的作用,以它为靶点治疗白血病,尤其是复发和难治性白血病,可能是一条有希望的途径。
This study was aimed to compare the expression level of eIF4E in patients with leukemia and normal controls, and to explore its role in leukemogenesis. White blood cells were collected in 76 leukemia patients and 10 healthy volunteers. The mRNA and protein expressions of eIF4E were detected by QT-PCR and Western blot in 39 cases of acute myeloid leukemia （AML）, 15 cases of chronic myeloid leukemia （CML）, 22 cases of acute lymphocytic leukemia（ALL） and 10 healthy volunteers as normal controls. The results demonstrated that compared with normal controls, the absolute expression levels of eIF4E mRNA increased in patients with AML, ALL and CML in blastic phase （P 〈 0.05 ）, but had no significant change between groups of CML in chronic and accelerated phase although some increasing in group of CML in accelerated phase. The relative expression level of eIF4E mRNA had no significant change in AML,ALL, CML groups except the two subtypes of leukemia M4 and M5. Furthermore, the protein expression level in group of CML in accelerated phase and blastic phase and all acute leukemia patients including AML and ALL were higher than that in normal controls （ P 〈 0.05 ）. It is concluded that although its mRNA relative expressions had no significant change in most leukemia patients, the absolute expression level of eIF4E mRNA and its protein expression is up-regulated in most leukemia patients, which may play an important role in leukemogenesis, so the eIF4E may be a promising target for leukemia therapy and eIF4E-targeted therapy may be an option especially for the relapse and refractory leukemia.
出处
《中国实验血液学杂志》
CAS
CSCD
北大核心
2013年第1期1-6,共6页
Journal of Experimental Hematology
基金
福建省血液病学重点实验室经费(编号2009J1004)
国家自然科学基金(编号30572132)
福建省自然科学基金(编号C0410029)
福建医科大学基金(编号FJGXY04022)
作者简介
通讯作者：胡建达，教授，主任医师，博士生导师．电话：（0591）83357896-8377．E-mail：jdhu@medmail．com．cn
